Point72 Asset Management L.P. raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 105.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,756,122 shares of the biopharmaceutical company’s stock after acquiring an additional 1,413,722 shares during the […]
Point72 Asset Management L.P. lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 105.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,756,122 shares of the biopharmaceutical company’s stock after purchasing an additional 1,413,722 shares during the period. Point72 Asset Management L.P. […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) SVP Diane C. Young sold 45,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the transaction, the senior vice president now owns 2,115 shares […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) VP Elizabeth Crowley sold 15,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the completion of the transaction, the vice president now directly owns 9,074 shares […]
/PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation...
The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of
Bellevue Group AG boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 27.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,416,296 shares of the biopharmaceutical company’s stock after purchasing an additional 516,296 shares during the […]
04.06.2024 - HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the transaction, the vice president now directly owns 9,074 shares […]
Crestline Management LP boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 6.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 67,243 shares of the biopharmaceutical company’s stock after purchasing an additional 4,133 shares during the period. Crestline Management LP […]